Invited commentary.
Francis
John L
JL
Center for Hemostasis and Thrombosis, Florida Hospital Center for Hemostasis and Thrombosis, 2501 N Orange Ave, Suite 786, Orlando, FL 32804, USA. john.francis@flhosp.org
D000925:Anticoagulants / Q000009:adverse effects* / Q000276:immunology; D006348:Cardiac Surgical Procedures; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D000075202:Contraindications; D003871:Dermatan Sulfate / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006497:Heparan Sulfate / Q000627:therapeutic use; D006801:Humans; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000276:immunology; D011183:Postoperative Complications / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D011184:Postoperative Period; D012701:Serotonin / Q000378:metabolism; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006497:Heparan Sulfate; D010978:Platelet Factor 4; D012701:Serotonin; C035838:danaparoid